Key result
Antianginal medications improve symptoms and quality of life in stable angina, but robust data from large randomized controlled trials are still lacking for patients with refractory angina.
A contemporary review emphasizing tailored medical therapy for angina and the need for invasive phenotyping in patients with non-obstructed coronary arteries.
Answers are grounded in this paper and cite their sources.
Supports tailored antianginal therapy in stable angina; leaves open evidence-based approaches for refractory angina.
Angina is the main symptom of ischemic heart disease; mirroring a mismatch between oxygen supply and demand. Epicardial coronary stenoses are only responsible for nearly half of the patients presenting with angina; whereas in several cases; symptoms may underlie coronary vasomotor disorders; such as microvascular dysfunction or epicardial spasm. Various medications have been proven to improve the prognosis and quality of life; representing the treatment of choice in stable angina and leaving revascularization only in particular coronary anatomies or poorly controlled symptoms despite optimal medical therapy. Antianginal medications aim to reduce the oxygen supply-demand mismatch and are generally effective in improving symptoms; quality of life; effort tolerance and time to ischemia onset and may improve prognosis in selected populations. Since antianginal medications have different mechanisms of action and side effects; their use should be tailored according to patient history and potential drug-drug interactions. Angina with non-obstructed coronary arteries patients should be phenotyped with invasive assessment and treated accordingly. Patients with refractory angina represent a higher-risk population in which some therapeutic options are available to reduce symptoms and improve quality of life; but robust data from large randomized controlled trials are still lacking.
No takes yet. Share an insight, caveat, or question.
Manfredi et al. (2022) conducted a review in Angina. Antianginal medications was evaluated. Antianginal medications improve symptoms and quality of life in stable angina, but robust data from large randomized controlled trials are still lacking for patients with refractory angina.
Synapse has enriched 10 related papers. Consider them for comparative context: